Xuewei Cui
About
Xuewei Cui is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery.
According to data from OpenAlex, Xuewei Cui has authored 37 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Endocrinology, Diabetes and Metabolism, 17 papers in Molecular Biology and 9 papers in Surgery. Recurrent topics in Xuewei Cui's work include Diabetes Treatment and Management (20 papers), Metabolism, Diabetes, and Cancer (15 papers) and Diabetes Management and Research (8 papers). Xuewei Cui is often cited by papers focused on Diabetes Treatment and Management (20 papers), Metabolism, Diabetes, and Cancer (15 papers) and Diabetes Management and Research (8 papers). Xuewei Cui collaborates with scholars based in United States, China and Germany. Xuewei Cui's co-authors include Juan P. Frías, Laura Fernández Landó, Julio Rosenstock, Axel Haupt, Katelyn Brown, Brandon K. Bergman, Bing Liu, Melanie J. Davies, Federico C. Pérez Manghi and Shweta Urva and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Clinical Endocrinology & Metabolism.
In The Last Decade
Xuewei Cui
35 papers receiving 3.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Xuewei Cui United States | 16 | 2.9k | 1.5k | 1.2k | 1.1k | 865 | 37 | 3.8k | ||
| Zvonko Miličević United States | 26 | 3.7k 1.3× | 1.6k 1.1× | 1.3k 1.1× | 1.2k 1.1× | 938 1.1× | 83 | 4.5k | ||
| Salvatore Calanna Denmark | 20 | 2.6k 0.9× | 1.1k 0.7× | 1.3k 1.1× | 1.0k 1.0× | 1.0k 1.2× | 27 | 4.0k | ||
| Laura Fernández Landó United States | 18 | 2.6k 0.9× | 1.1k 0.7× | 990 0.9× | 754 0.7× | 763 0.9× | 52 | 3.2k | ||
| Jenny Han United States | 18 | 3.3k 1.1× | 1.5k 1.0× | 714 0.6× | 1.5k 1.4× | 356 0.4× | 29 | 3.6k | ||
| Kristin Taylor United States | 17 | 3.8k 1.3× | 1.7k 1.1× | 854 0.7× | 1.9k 1.7× | 349 0.4× | 26 | 4.3k | ||
| Carol Wysham United States | 23 | 2.6k 0.9× | 1.0k 0.7× | 635 0.5× | 922 0.9× | 344 0.4× | 77 | 3.1k | ||
| Yukiko Onishi Japan | 33 | 1.6k 0.5× | 1.6k 1.1× | 394 0.3× | 692 0.6× | 890 1.0× | 76 | 3.7k | ||
| Murray Stewart United Kingdom | 31 | 2.2k 0.7× | 1.2k 0.8× | 442 0.4× | 975 0.9× | 358 0.4× | 68 | 3.1k | ||
| Robert G. Brodows United States | 27 | 3.2k 1.1× | 1.4k 0.9× | 697 0.6× | 1.3k 1.2× | 478 0.6× | 50 | 3.8k | ||
| Kazunori Utsunomiya Japan | 32 | 1.6k 0.6× | 1.3k 0.8× | 323 0.3× | 807 0.7× | 582 0.7× | 152 | 4.0k |
Countries citing papers authored by Xuewei Cui
Since
Specialization
Citations
This map shows the geographic impact of Xuewei Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuewei Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuewei Cui more than expected).
Fields of papers citing papers by Xuewei Cui
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Xuewei Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuewei Cui. The network helps show where Xuewei Cui may publish in the future.
Co-authorship network of co-authors of Xuewei Cui
This figure shows the co-authorship network connecting the top 25 collaborators of Xuewei Cui. A scholar is included among the top collaborators of Xuewei Cui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xuewei Cui. Xuewei Cui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cui, Xuewei, et al.. (2025). DNA damage response and cell fate decisions across the lifespan: from fetal development to age-related respiratory diseases. Cell & Bioscience. 15(1). 114–114.
2.
Cui, Xuewei, et al.. (2025). Enhancing the physiological characteristics of chimeric antigen receptor natural killer cells by synthetic biology. Frontiers in Immunology. 16. 1592121–1592121.
3.
Lingvay, Ildiko, Ofri Mosenzon, Katelyn Brown, et al.. (2023). Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovascular Diabetology. 22(1). 66–66.
4.
Viljoen, Adie, Kevin M. Pantalone, Rodolfo J. Galindo, et al.. (2023). Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3. Diabetes Therapy. 14(5). 925–936.
5.
Viljoen, Adie, Kevin M. Pantalone, Rodolfo J. Galindo, et al.. (2023). Patients with Type 2 Diabetes Reach Glycaemic Targets Faster with Tirzepatide Compared to Semaglutide and Titrated Insulin Degludec. Diabetologie und Stoffwechsel. 18(S 01). S63–S64.
6.
Dai, Zhujiang, Xuewei Cui, Yuegui Guo, et al.. (2023). Innovative molecular subtypes of multiple signaling pathways in colon cancer and validation of FMOD as a prognostic-related marker. Journal of Cancer Research and Clinical Oncology. 149(14). 13087–13106.
7.
Frías, Juan P., Melanie J. Davies, Julio Rosenstock, et al.. (2022). Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2). Diabetologie und Stoffwechsel. 17(S 01). S21–S22.
8.
Frías, Juan P., Melanie J. Davies, Julio Rosenstock, et al.. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 385(6). 503–515.
9.
Zhang, Yifei, Yiming Li, Xia Zhao, et al.. (2021). Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study. Advances in Therapy. 39(1). 488–503.
10.
Liu, Tianjing, Haifeng Zong, Xiaoyu Chen, et al.. (2021). Toll-like receptor 4-mediated necroptosis in the development of necrotizing enterocolitis. Pediatric Research. 91(1). 73–82.
11.
Rosenstock, Julio, Carol Wysham, Juan P. Frías, et al.. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 398(10295). 143–155.
12.
Frías, Juan P., Michael A. Nauck, Joanna Van, et al.. (2020). Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens. Diabetes Obesity and Metabolism. 22(6). 938–946.
13.
Urva, Shweta, Tamer Coşkun, Corina Loghin, et al.. (2020). The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists. Diabetes Obesity and Metabolism. 22(10). 1886–1891.
14.
Shi, Yongyan, et al.. (2020). Intestinal vitamin D receptor knockout protects from oxazolone-induced colitis. Cell Death and Disease. 11(6). 461–461.
15.
Cui, Xuewei, et al.. (2019). Effects of Lactobacillus reuteri DSM 17938 in preterm infants: a double-blinded randomized controlled study. The Italian Journal of Pediatrics/Italian journal of pediatrics. 45(1). 140–140.
16.
Coşkun, Tamer, Kyle W. Sloop, Corina Loghin, et al.. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 18. 3–14.
17.
Frías, Juan P., Michael A. Nauck, Joanna Van, et al.. (2018). Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. The Lancet. 392(10160). 2180–2193.
18.
Peña, Amparo de la, et al.. (2017). No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. Clinical Pharmacokinetics. 56(11). 1415–1427.
19.
Heathman, Michael, Xuewei Cui, Jennifer A. Martin, et al.. (2015). Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials. Clinical Pharmacokinetics. 55(5). 625–634.
20.
Peña, Amparo de la, Corina Loghin, & Xuewei Cui. (2015). Abstract #252: Once Weekly Dulaglutide may be Coadministered with Warfarin Without Dose Adjustment. Endocrine Practice. 21. 50–50.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Zvonko Miličević Breakdown of academic impact, for papers by Salvatore Calanna Breakdown of academic impact, for papers by Laura Fernández Landó Breakdown of academic impact, for papers by Jenny Han Breakdown of academic impact, for papers by Kristin Taylor Breakdown of academic impact, for papers by Carol Wysham Breakdown of academic impact, for papers by Yukiko Onishi Breakdown of academic impact, for papers by Murray Stewart Breakdown of academic impact, for papers by Robert G. Brodows Breakdown of academic impact, for papers by Kazunori Utsunomiya